InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (5 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
5
T+90 hit rate
0%
T+90 mean return
-37.1%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Lucera Erick, Chief Financial Officer. Insider active across 3 companies, notably Dyne Therapeutics, Inc.. Aggregated, 10 filings have been recorded. Split: 2 buys · 5 sells. Total volume traded: €195k. Activity tracked since 16 March 2023. The latest transaction was disclosed on 13 May 2026 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations10 total
2,362 sharesCommon StockSEC:0001193125-26-285505:0
1,448 shares@ US$18.360.0008% mcap50.0% of flowCommon StockSEC:0001193125-26-223961:0
1,448 shares@ US$18.360.0008% mcap100.0% of flowCommon StockSEC:0001193125-26-223961
66,100 shares0Common StockSEC:0000950170-25-048601:0
4,109 shares@ US$1.71085.5% of flowCommon StockSEC:0001650664-25-000027:0
39,266 shares@ US$0.396452.3% of flowCommon StockSEC:0001493152-24-032675:0
Ideal exit: 11 May 2025 (T+270)
22,337 shares@ US$5.614294.5% of flowCommon StockSEC:0001650664-24-000044:0
35,300 shares0Common StockSEC:0001650664-24-000019:0
77,900 shares0Common StockSEC:0001415889-23-008293:0
2,000 shares@ US$6.81747.7% of flowCommon StockSEC:0001493152-23-008245:0
Ideal exit: 11 Dec 2023 (T+270)
10 of 10 declarations
About Lucera Erick
Erick Lucera serves as Chief Financial Officer of Dyne Therapeutics, Inc. He oversees the company's financial operations, including budgeting, financial analysis, and reporting. With a strong background in corporate finance, he plays a key role in Dyne Therapeutics' financial strategy. Erick Lucera is committed to ensuring financial transparency and supporting the company's sustainable growth.
